Biotech entity
pharma is the sole category represented across all 2 tracked stories. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 175-day span, the pace is roughly 0.1 stories per week.
Last mentioned: Aug 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 2 tracked stories. Bristol Myers Squibb is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 175-day span, the pace is roughly 0.1 stories per week. Each story carries 2.5 original sources on average, compared with 3.5 for the broader beat in this window. The 5.5 average consequence score is below the beat benchmark of 6.1 in the same window. This profile follows 2 Biotech stories mentioning Halozyme Therapeutics across the period from February 19, 2026 to August 12, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 721 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Halozyme Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Source: dailypolitical.com · themarketsdaily.com
Halozyme Therapeutics reported a strong revenue beat of $451 million for the fourth quarter, driven by its ENHANZE platform royalties, yet surprised investors with a significant non-GAAP EPS miss of $2.44. The discrepancy suggests substantial one-time charges or strategic shifts that contrast with the company's robust top-line growth.
Source: Seeking Alpha · Seeking Alpha
Halozyme Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
